David A. Siegel Hookipa Pharma Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.59 - $1.04 $6,667 - $11,752	11,300 Added 31.74%	46,900 $27,000
Q1 2024 May 15, 2024	BUY	$0.61 - $0.83 $21,716 - $29,548	35,600 New	35,600 $25,000
Q2 2023 Aug 14, 2023	BUY	$0.71 - $1.97 $12,567 - $34,869	17,700 New	17,700 $15,000
Q1 2022 May 16, 2022	SELL	$1.26 - $2.52 $319,536 - $639,072	-253,600 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.33 - $5.94 $391,440 - $997,920	168,000 Added 196.26%	253,600 $591,000
Q3 2021 Nov 15, 2021	BUY	$5.89 - $9.35 $435,271 - $690,965	73,900 Added 631.62%	85,600 $504,000
Q2 2021 Aug 16, 2021	SELL	$9.16 - $19.51 $106,256 - $226,316	-11,600 Reduced 49.79%	11,700 $107,000
Q1 2021 May 17, 2021	BUY	$10.64 - $14.7 $247,912 - $342,510	23,300 New	23,300 $313,000

677K

Ticker HOOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,654,500
Market Cap $106M
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.